Seres Therapeutics MCRB is set to give its latest quarterly earnings report on Wednesday, 2025-08-06. Here's what investors need to know before the announcement.
Analysts estimate that Seres Therapeutics will report an earnings per share (EPS) of $-2.45.
The market awaits Seres Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Earnings History Snapshot
During the last quarter, the company reported an EPS beat by $2.15, leading to a 16.1% drop in the share price on the subsequent day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.60 | -4 | -4.8 | -5.4 |
| EPS Actual | 3.75 | -1.6 | -6.6 | -4.4 |
| Price Change % | -16.0% | 8.0% | 0.0% | 9.0% |
Market Performance of Seres Therapeutics's Stock
Shares of Seres Therapeutics were trading at $14.78 as of August 04. Over the last 52-week period, shares are down 18.66%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
